In vitro studies using GPER agonists and LoVo cells have revealed that GPER by affecting the EGFR/ERK/c-Fos/AP1 signaling pathway is responsible for regulation of FASN expression and modulates the potential for CRC cells proliferation and migration (56). Here, FASN is linked to colorectal carcinoma.